Characteristics of study subjects
| Discovery cohort | Validation cohort | |
| n=127 | n=77 | |
| Age, years | 54±17 | 57±17 |
| Body mass index, kg/m2 | 28±7 | 29±8 |
| Female, n (%) | 89 (70) | 47 (61) |
| Caucasian ethnicity, n (%) | 111 (87) | 58 (75) |
| Vasoresponder, n (%) | 8 (6) | – |
| Heritable PAH, n (%) | 9 (7) | 2 (3) |
| Baseline haemodynamics | ||
| Mean pulmonary artery pressure, mm Hg | 52±16 | 49±12 |
| Pulmonary artery wedge pressure, mm Hg | 12±5 | 11±5 |
| Pulmonary vascular resistance, WU | 11±6 | 11±5 |
| Cardiac output, L/min | 4.3±1.6 | 3.9±1.6 |
| Functional capacity | ||
| 6MWD, m | 313±158 | 263±162 |
| WHO-FC III/IV, n (%) | 94 (74) | 55 (72) |
| Laboratory investigations | ||
| NT-proBNP, ng/mL | 711±839 | 1316±1287 |
| Bilirubin, μmol/L | 14±10 | 18±9 |
| Creatinine, mg/dL | 86±31 | 99±50 |
| C reactive protein, mg/dL | 5±7 | 9±12 |
| Medication | ||
| Phosphodiesterase type 5 inhibitor, n (%) | 97 (76) | 42 (54) |
| Endothelin receptor antagonist, n (%) | 51 (40) | 47 (61) |
| Prostacyclin analogue, n (%) | 23 (18) | 8 (10) |
| Statin, n (%) | 38 (30) | 21 (27) |
| Oral anticoagulation, n (%) | 100 (79) | 51 (66) |
| ACE inhibitor, n (%) | 19 (15) | 23 (30) |
| Diuretics, n (%) | 58 (46) | 48 (62) |
| Aldosterone antagonists, n (%) | 47 (37) | 33 (43) |
| Comorbidities | ||
| Atrial fibrillation/flutter, n (%) | 21 (17) | 16 (21) |
| Diabetes mellitus, n (%) | 24 (19) | 19 (25) |
| Coronary artery disease, n (%) | 19 (15) | 21 (27) |
| COPD, n (%) | 10 (8) | 16 (21) |
| Systemic hypertension, n (%) | 38 (30) | 25 (33) |
Means and SDs or counts are given.
COPD, chronic obstructive pulmonary disease; 6MWD, 6 min walk distance; NT-proBNP, N-terminal pro-brain natriuretic peptide; WC, Wood units; WHO-FC, WHO functional class.